Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

20.14 +0.52 (+2.65%)
Streaming Delayed Price Updated: 10:50 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
From Akero Therapeutics Inc.
Via GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Akero Therapeutics, Inc. (AKRO)
From Robbins LLP
Via GlobeNewswire
AKERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Akero Therapeutics: Q4 Earnings Insights
Via Benzinga
11 Analysts Have This to Say About Akero Therapeutics
Via Benzinga
ROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
From Rosen Law Firm
Via Business Wire
AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
AKERO THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO
From Kahn Swick & Foti, LLC
Via Business Wire
AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO)
From Abraham, Fruchter & Twersky, LLP
Via GlobeNewswire
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Announces Proposed Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Akero Therapeutics' Stock Is Soaring Monday - Here's Why
Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, marking a major milestone in liver disease treatment. 
Via Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing. 
Via Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
From Akero Therapeutics Inc.
Via GlobeNewswire
Super Micro Computer, Deckers Outdoor And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 50 points on Monday. Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in today’s pre-market... 
Via Benzinga
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data 
From Akero Therapeutics Inc.
Via GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
Via Investor's Business Daily
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results. 
Via Benzinga
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
From Akero Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.